News Agilent Technologies, Inc.

Equities

A

US00846U1016

Market Closed - Nyse Other stock markets 04:00:01 2024-05-03 pm EDT			5-day change	1st Jan Change
139.4 ^USD	+1.40%		+1.24%	+0.30%

May. 01	Agilent Technologies Says Padraig McDonnell Assumes CEO Role	MT
May. 01	Agilent Technologies Appoints Padraig McDonnell CEO	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agilent to Announce Second-Quarter Fiscal Year 2024 Financial Results May 29	May. 02	BU
Agilent Technologies Inc. - Padraig McDonnell Assumes Agilent CEO Role	May. 02	AQ
Agilent Technologies Says Padraig McDonnell Assumes CEO Role	May. 01	MT
Agilent Technologies Appoints Padraig McDonnell CEO	May. 01	MT
Padraig McDonnell Assumes Agilent CEO Role	May. 01	BU
Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution	May. 01	BU
Agilent Announces the NovoCyte Opteon, A Cutting-Edge Spectral Flow Cytometry Solution	May. 01	CI
Agilent Names Simon May to Lead Diagnostics and Genomics Group	Apr. 29	BU
Agilent Technologies, Inc. Appoints Simon May as President of the Diagnostics and Genomics Group, Effective May 6, 2024	Apr. 29	CI
Bernstein Adjusts Agilent Technologies' Price Target to $130 From $127	Apr. 22	MT
Bernstein Adjusts Price Target on Agilent Technologies to $130 From $127	Apr. 22	MT
Baird Adjusts Price Target on Agilent Technologies to $147 From $143, Outperform Rating Kept	Apr. 22	MT
Reitmans (Canada) Limited Reports Fiscal 2024 and Fourth Quarter Fiscal 2024 Financial Results	Apr. 18	AQ
Agilent Receives Scientists Choice Awards for Sustainability	Apr. 17	AQ
Agilent Receives Scientists' Choice Awards for Sustainability	Apr. 16	BU
Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay	Apr. 15	BU
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed	Apr. 09	RE
Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	Apr. 09	MT
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial	Apr. 08	CI
Have investors resigned themselves to fewer rate cuts?	Apr. 05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Agilent Technologies, Inc.

Equities

A

US00846U1016

Summary

Filters